StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Funny

<< Previous

Bullboard Posts

Next >>

Comment by IainCaimbeulon Apr 10, 2024 11:18am

109 Views

Post# 35981237

RE:RE:RE:Funny

"The GEM funds would be excessively dilutive at this time and require a higher share price than we currently have. So yes we still have that funding available until November 2025, it currently does not positively support us".

So, why don't they just use Aristotle revenue to pay the auditors? Gufaw, gufaw, gufaw. Because we are broke?

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?